post void residual urine evaluation was performed. Mann-Whitney, chi square and binary logistic regression analysis were performed RESULTS: Overall 126 patients were enrolled with a median age of 72 (65/78) years and a median BMI of 25 (23/26) kg/m2. Median prostate volume was 74 (56/102) ml, median DWT was 5 mm (4.6/10) and median IPP was 5 mm (3.5/12). Hydronephrosis, was found in 24/ 126 (19%) INTRODUCTION AND OBJECTIVES: Benign prostatic hyperplasia (BPH) affects more than half of men over age 50 and up to 90% of men over age 80. The estimated economic burden of BPH in the United States is $4 billion annually. Currently accepted treatments include watchful waiting, pharmacotherapy, and procedural interventions. The purpose of this study is to identify the focus of current research in the field and assess for correlation with funding sources for potential scientific advances in the treatment of BPH.
INTRODUCTION AND OBJECTIVES:
Benign prostatic hyperplasia (BPH) affects more than half of men over age 50 and up to 90% of men over age 80. The estimated economic burden of BPH in the United States is $4 billion annually. Currently accepted treatments include watchful waiting, pharmacotherapy, and procedural interventions. The purpose of this study is to identify the focus of current research in the field and assess for correlation with funding sources for potential scientific advances in the treatment of BPH.
METHODS: We investigated clinicaltrials.gov, the online registry of national and international clinical research studies provided by the United States National Library of Medicine. The site was queried for benign prostatic hyperplasia and benign prostatic hypertrophy. Trials with recruiting, active, and enrolling status were stratified by intervention, primary investigator sub-specialty, and source of funding.
RESULTS: A total of sixty-five unique studies were identified. Primary investigators included forty-two (64.6%) urologists, eighteen (27.7%) radiologists and five (7.7%) others. Twenty-nine (44.6%) studies evaluated urology procedures including more than 15 distinct tools to endoscopically treat BPH. Twenty-one (32.3%) studies evaluated radiology-guided procedures, primarily related to prostate artery embolization. Eight (12.3%) trials examined drug therapies and seven (10.8%) were non-interventional. Of the trials examining drug therapies, one examined a novel drug. Funding sources included industry in twenty-three (35.4%) trials, a United States Federal Agency in one (1.5%) trial and other sources (such as educational institutions, hospital, and private funding) in 45 (69.2%) trials.
CONCLUSIONS: More than 75% of contemporary active clinical trials in BPH are focused on procedural interventions, with sparse investigation of novel drug classes. This indicates the need for increased investigation into novel drug therapies. One trial received federal funding, highlighting a disparity between disease prevalence and federal research support.
Source of Funding: None

PD19-03 CORRELATION OF ALPHA BLOCKER WITH DEMENTIA IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA: A NATIONWIDE POPULATION-BASED STUDY USING THE NATIONAL HEALTH INSURANCE SERVICE DATABASE
Tae Bum Sik, Hoon Choi, Jae Young Park, Bae Jae Hyun, Byung Jo Jeon, Ansan, Korea, Republic of; Hong Chung, Chungju, Korea, Republic of; Sung Tae Cho*, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: To evaluate the association between alpha-blockers and dementia in patients with benign prostate hyperplasia (BPH).
METHODS: Using the National Health Insurance Service database of the entire Korean adult patient population with BPH, data on alpha-blockers and dementia between January 2011 and December 2011 were analyzed. These patients were followed-up until September 2017. We excluded patients who were previously diagnosed with cognitive dysfunction or dementia, or who had a history of a cerebral event. We tested the effect of alpha-blockers on the risk of dementia using propensity score-matched Cox proportional hazard regression models and Kaplan Meier-survival analysis.
RESULTS: During a mean follow-up period of 1,496 (AE821.8) days, all inclusion and exclusion criteria were met by 65,481 patients with BPH. After propensity score-matching, the incidence of dementia was 18.5% in the tamsulosin cohort, 19.1% in the doxazosin cohort, 21.2% in the terazosin cohort, 18.0% in the alfuzosin cohort, and 21.3% in the no BPH medication cohort. 
